Eikon Therapeutics, Inc.
EIKN
Positions held
Your positionsEIKN isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $406.24M | Enterprise value | $127.28M | Trailing P/E | — | Forward P/E | -1.18 |
| PEG | — | Price / book | 0.87 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | — | ROA | — | Debt / equity | 0.54 |
| Current ratio | 9.89 | Free cash flow | — | Analyst recommendation | none | Mean target | $24.60 |
| 52w high | $17.40 | 52w low | $7.02 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$88.4M | -$83.0M | -$79.7M | -$71.1M | -$105M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$93.4M | -$87.3M | -$83.2M | -$74.8M | -$110M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — |
| Net income | -$324M | -$244M | -$242M |
| Gross margin | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$339M | -$260M | -$266M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-03 · Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
2026-08-26 · Eikon Therapeutics to Participate in Investor Conferences in September 2026
2026-08-22 · Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004
2026-08-13 · Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
2026-08-11 · Eikon Therapeutics Selects Dose in Phase 2/3 Trial of Investigational Melanoma Treatment
2026-07-27 · Eikon Therapeutics Doses First Patient in Phase 2/3 Trial for EIK1001 in Non-Small Cell Lung Cancer
Price (daily)
Full chart · RSI · MACD · patterns